Clinical Trial Update: Dose-escalation Study of Oral CX-4945 [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of CX-4945 in patients with various cancers is underway, including breast cancer, inflammatory breast cancer, Castleman's disease,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Castleman Disease
• Inflammatory Breast Cancer
• Multiple Myeloma

Drugs mentioned

• CX-4945 (silmitasertib)

Snippet

Sponsor: Cylene Pharmaceuticals | Conditions: Advanced Solid Tumors, Breast Cancer | Phase 1 | Status: UNKNOWN